Genzyme to Build New R&D Center ...(se patientsin need. Approximately 125 pa...)

Date:4/22/2008

se patients in need. Approximately 125 patients are being treated in China through the Gaucher Initiative, Genzyme's humanitarian partnership with Project HOPE. Last year, the company began a collaboration with the Chinese firm Sunway Biotech Co. Ltd. with the goal of bringing a gene therapy for cardiovascular disease to patients in China and Genzyme is seeking to form additional partnerships with local companies.

Consistent with Genzyme's commitment to the environment and corporate responsibility, the new Beijing facility will feature an attractive architectural design and innovative green features that will create a healthy and comfortable workplace for employees, and reduce its environmental impact. The company intends to seek certification for the building with the U.S. Green Building Council's Leadership in Energy and Environmental Design (LEED) rating system. Genzyme's global corporate headquarters, Genzyme Center, achieved the highest LEED rating, and all of the company's facilities worldwide are being built to high environmental standards. Genzyme is conducting major R&D and manufacturing expansion projects in the United States, Belgium, France, the United Kingdom and the Netherlands, and is rapidly expanding its commercial operations in countries around the world.

Genzyme's new Beijing facility will be located in Zhongguancun (ZGC) Life Science Park, an area dedicated to academic and government research centers as well as pharmaceutical and biotechnology companies. The 200,000 square-foot building will be constructed with low-impact environmental techniques and methods, and will incorporate a range of environmentally responsible features, including: a living roof to reduce pollution caused by storm water runoff; a solar thermal system that will provide a significant portion of the building's hot water and reduce its energy consumption; and low-flow fixtures to limit water usage.

An all-glass exterior will provide employees with signific
'/>"/>

SOURCE Genzyme Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Genzyme Provides Update on Myozyme(R) Manufacturing
2. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
3. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
4. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
5. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
6. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
7. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
8. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
9. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors